Internship

Biometrics Summer Intern

Posted on 12/20/2024

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$25 - $31Hourly

San Carlos, CA, USA

Must work at the Redwood City office for the duration of the internship, no relocation available.

Category
Bioinformatics
Computational Biology
Biology & Biotech
Required Skills
Python
R
Requirements
  • Strong understanding of statistical concepts and methodologies
  • Proficiency in at least one programming language for data manipulation and advanced analytics (R/SAS/Python or other language), familiarity with multiple statistical software and programming languages is a plus
  • Excellent problem-solving skills and attention to detail
  • Solid communication skills to convey complex findings in a comprehensible manner
  • Ability to work independently and collaboratively in a dynamic team environment
  • Must be able to complete at least 10 consecutive weeks between June and August and it is a full-time internship (40 hours per week)
  • Must be able to work at our Redwood City office for the duration of the internship, no relocation available
  • Currently pursuing a degree in statistics, mathematics, data science or a related field
Responsibilities
  • Collaborate with all 3 functions within Biometrics (statistics, clinical data management, statistical programming) to ensure the highest quality of source and derived data
  • Participate in cross-functional team meetings to understand project requirements and objectives
  • Participate in the design and execution of experiments to collect relevant data
  • Clean, preprocess, and validate data to ensure data integrity and accuracy
  • Assist in the development and implementation of statistical models and algorithms
  • Conduct statistical analyses using R/Python/SAS (or other programming language) to extract meaningful insights from large datasets
  • Generate clear and concise reports (including graphical displays) summarizing analysis results for internal stakeholders
  • Learn about industry trends and advancements in data standards, statistical methods, and programming languages
  • Deliver a department presentation at the end of the program
  • Participate as a member of the 2025 intern team group project that includes a company-wide presentation

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Company Stage

IPO

Total Funding

$42.6M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

23%

1 year growth

31%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in cortisol modulation for mental health expands Corcept's market potential.
  • Advancements in biomarker discovery enhance the effectiveness of Corcept's treatments.
  • The rise of personalized medicine offers opportunities for targeted therapies by Corcept.

What critics are saying

  • Teva's antitrust lawsuit could lead to significant legal expenses for Corcept.
  • Roberto Vieira's appointment may divert resources from Corcept's core focus on cortisol.
  • Recent stock offering may dilute shareholder value, indicating potential financial challenges.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few direct competitors.
  • Their flagship product, Korlym, is the first FDA-approved treatment for Cushing's syndrome.
  • Corcept has discovered over 1,000 selective cortisol modulators, showcasing strong R&D capabilities.

Help us improve and share your feedback! Did you find this helpful?